Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
暂无分享，去创建一个
M. Papotti | A. Priola | N. Fazio | M. Brizzi | L. Dogliotti | G. Biasco | A. D’Avolio | L. Bodei | M. Volante | A. Ferrero | A. Berruti | V. Amoroso | E. Nobili | M. Torta | N. Birocco | L. Tozzi